在现实环境中探索ursodeoxycholic acid治疗对COVID-19的影响
Christophe Corpechot1,2, Marie Verdoux3, Marie Frank-Soltysiak4
1Reference Center for Inflammatory Biliary Diseases and Autoimmune Hepatitis, European Reference Network on Hepatological Diseases (ERN Rare-Liver), Saint-Antoine Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France.
Journal of medical virology
|January 19, 2024
概括
在患有慢性肝病的患者中, Ursodeoxycholic acid (UDCA) 并没有显著降低严重COVID-19住院的风险. 这项研究发现UDCA治疗与2019年冠状病毒病住院或ICU入院的风险降低之间没有关联.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 传染性疾病 传染性疾病
- 药理学 药理学是指药理学的学科.
背景情况:
- Ursodeoxycholic 酸 (UDCA) 已经显示出降低对 SARS-CoV-2 感染的易感性和改善 COVID-19 结果的潜力.
- 然而,支持UDCA对严重COVID-19的保护作用的临床证据有限且相互矛盾.
研究的目的:
- 评估UDCA暴露与因COVID-19住院治疗的风险之间的关联.
- 评估UDCA对慢性肝病 (CLD) 患者严重COVID-19结局的影响,包括ICU入院或死亡.
主要方法:
- 进行了一项大型的多中心队列研究和一项嵌套病例控制研究.
- 在疫苗接种前的流行病期间,对患有CLD的患者进行了随访.
- 严重的COVID-19被定义为需要住院的SARS-CoV-2感染;二级终点包括ICU入院或死亡.
主要成果:
- 队列分析包括10,147名患者 (1322名暴露于UDCA),随访时间为21,867人年.
- 嵌套病例控制研究涉及88名住院COVID-19患者和840名匹配对照.
- 两种分析都没有显示出与UDCA暴露相关的COVID-19住院风险 (aOR:0.48 [0.20-1.19]和0.93 [0.26-3.29]) 或严重结果 (ICU入院/死亡) 的显著降低.
结论:
- 在大量患有CLD的患者中,UDCA暴露与严重COVID-19的风险降低无关.
- 研究结果表明,UDCA在这个患者群体中对2019年严重的冠状病毒病没有显著的保护作用.
相关概念视频
01:29Drugs for Treatment of Ulcerative Colitis in IBD
142
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
142
01:17Drugs for Treatment of Diarrhea-Predominant IBS
176
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
176
01:29Chronic Pancreatitis II: Collaborative Care
92
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Assessment:
92